Vorsetuzumab mafodotin (SGN-75) is an

antibody-drug conjugate Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 phar ...

(ADC) directed to the protein

CD70 CD70 (Cluster of Differentiation 70) is a protein that in humans is encoded by ''CD70'' gene. CD70 is a ligand for CD27. Clinical significance The CD70 protein is expressed on highly activated lymphocytes (like in T- and B-cell lymphomas). It i ...

designed for the treatment of

cancer Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal b ...

. It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a

cytotoxic agent Cytotoxicity is the quality of being toxic to cells. Examples of toxic agents are an immune cell or some types of venom, e.g. from the puff adder (''Bitis arietans'') or brown recluse spider (''Loxosceles reclusa''). Cell physiology Treating cell ...

. This drug was developed by Seattle Genetics, Inc. The drug completed phase I clinical trials for

renal cell carcinoma Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the Proximal tubule, proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cance ...

,Clinical trials for SGN-7
"Clinicaltrials.gov"
/ref> but development was discontinued in 2013.Seattle Genetics Third Quarter 2013 Financial Report
/ref> No reason was given but SG plan to start clinical trials of SGN-CD70A in 2014.

References

{{monoclonal-antibody-stub Monoclonal antibodies for tumors Antibody-drug conjugates Experimental cancer drugs